Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for various diseases. Its primary products include EYLEA (approximately 40% of revenue), Dupixent (around 30%), and Praluent (about 10%), with the remainder coming from other treatments such as Libtayo and REGEN-COV. The company serves a global market, primarily targeting healthcare providers and patients with specific medical conditions. Factors supporting its endurance include a strong pipeline of drug candidates and established partnerships, while patent expirations and competition from biosimilars could limit its revenue growth over time.
—
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for various diseases. Its primary products include EYLEA (approximately 40% of revenue), Dupixent (around 30%), and Praluent (about 10%), with the remainder coming from other treatments such as Libtayo and REGEN-COV. The company serves a global market, primarily targeting healthcare providers and patients with specific medical conditions. Factors supporting its endurance include a strong pipeline of drug candidates and established partnerships, while patent expirations and competition from biosimilars could limit its revenue growth over time.
—
Daily adjusted close
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for various diseases. Its primary products include EYLEA (approximately 40% of revenue), Dupixent (around 30%), and Praluent (about 10%), with the remainder coming from other treatments such as Libtayo and REGEN-COV. The company serves a global market, primarily targeting healthcare providers and patients with specific medical conditions. Factors supporting its endurance include a strong pipeline of drug candidates and established partnerships, while patent expirations and competition from biosimilars could limit its revenue growth over time.